Systematic review of health economic models for assessment and diagnosis of dementia

Kwon, Joseph, Schoutens, Lisanne, Burden, Mitchell, Colam, Charlotte, Zhao, Sihao, Nezafat Maldonado, Behrouz, Blundell, Elizabeth, Krywonos, Anastasia, Jiang, Jingjing, Karagiannidou, Maria ORCID: 0000-0001-6996-4332, Jindra, Christoph, Vaci, Nemanja, Roberts, Nia, Wittenberg, Raphael ORCID: 0000-0003-3096-2721, Knapp, Martin ORCID: 0000-0003-1427-0215, Sanchez, Amparo Yovanna Castro, Roncancio-Diaz, Emilse, Potashman, Michele H, Thompson, Robin, Handels, Ron, Wolstenholme, Jane, Gray, Alastair M. and Landeiro, Filipa (2025) Systematic review of health economic models for assessment and diagnosis of dementia. Alzheimer’s & Dementia: Behavior & Socioeconomics of Aging. ISSN 2997-3805 (In Press)

	Text (Systematic review of health economic models for assessment and diagnosis of dementia - APPENDIX) - Accepted Version Pending embargo until 1 January 2100. Available under License Creative Commons Attribution. Download (667kB)
	Text (Systematic review of health economic models for assessment and diagnosis of dementia) - Accepted Version Pending embargo until 1 January 2100. Available under License Creative Commons Attribution. Download (541kB)

Abstract

INTRODUCTION: Timely diagnosis of dementia is a public health priority to enable risk modification and treatment access. This study systematically identifies and critically appraises health economic models of dementia assessment and diagnosis. METHODS: Inclusion criteria were: any dementia stage; evaluated strategy(ies) for initial assessment/diagnosis of dementia; health economic evaluation using decision modelling. Ten databases were searched for 2000-2024. Philips checklist was applied for quality assessment. Narrative synthesis appraised methodological features and issued decision-making recommendations. RESULTS: 32 studies were included. Six evaluated cerebrospinal fluid (CSF); 11 neuroimaging including amyloid-targeting positron emission tomography; three blood-based biomarkers; two genetic testing; and 10 early assessment/diagnosis strategies. Methodological limitations included non-consideration of capacity constraints. Decision-making recommendations generally affirmed current clinical guidelines: e.g., CSF to confirm Alzheimer’s disease is cost-effective (incremental cost-effectiveness ratio of £10,150 per quality-adjusted life-year gained versus no use). DISCUSSION: Methodological appraisal and decision-making recommendations should assist model development and evidence-based dementia diagnosis.

Item Type:	Article
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RA Public aspects of medicine
Date Deposited:	30 Jun 2025 14:33
Last Modified:	30 Jun 2025 14:33
URI:	http://eprints.lse.ac.uk/id/eprint/128590

Actions (login required)

View Item